Aliskiren hemifumarate structure
|
Common Name | Aliskiren hemifumarate | ||
|---|---|---|---|---|
| CAS Number | 173334-58-2 | Molecular Weight | 1219.59000 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C64H110N6O16 | Melting Point | 72-75?C | |
| MSDS | N/A | Flash Point | N/A | |
Use of Aliskiren hemifumarateAliskiren hemifumarate(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM.IC50 value: 1.5 nM [1]Target: reninin vitro: Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans [2].in vivo: Aliskiren hemifumarate (< 10 mg/kg, oral) inhibits plasma renin activity and lowers blood pressure in sodium-depleted marmosets[3].Once-daily oral treatment with Aliskiren hemifumarate lowers blood pressure effectively, with a safety and tolerability profile, in patients with mild-to-moderate hypertension[4]. |
| Name | Aliskiren hemifumarate |
|---|---|
| Synonym | More Synonyms |
| Description | Aliskiren hemifumarate(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM.IC50 value: 1.5 nM [1]Target: reninin vitro: Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans [2].in vivo: Aliskiren hemifumarate (< 10 mg/kg, oral) inhibits plasma renin activity and lowers blood pressure in sodium-depleted marmosets[3].Once-daily oral treatment with Aliskiren hemifumarate lowers blood pressure effectively, with a safety and tolerability profile, in patients with mild-to-moderate hypertension[4]. |
|---|---|
| Related Catalog | |
| References |
| Melting Point | 72-75?C |
|---|---|
| Molecular Formula | C64H110N6O16 |
| Molecular Weight | 1219.59000 |
| Exact Mass | 1218.80000 |
| PSA | 366.86000 |
| LogP | 9.88180 |
| Vapour Pressure | 1.59E-23mmHg at 25°C |
| InChIKey | RSFGNDXWVZPKJA-KVBHIGNWSA-N |
| SMILES | COCCCOc1cc(CC(CC(N)C(O)CC(C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.O=C(O)C=CC(=O)O |
| Storage condition | Hygroscopic, -20°C Freezer, Under Inert Atmosphere |
| Hazard Codes | Xi |
|---|
|
~97%
Aliskiren hemif... CAS#:173334-58-2 |
| Literature: CHEMO IBERICA, S. A.; CARCONE, Luca; MAGRONE, Domenico; BARRECA, Giuseppe; RASPARINI, Marcello; LI MING, Huan Patent: WO2013/14191 A1, 2013 ; Location in patent: Page/Page column 19; 20 ; |
|
~86%
Aliskiren hemif... CAS#:173334-58-2 |
| Literature: CHEMO IBERICA, S. A.; CARCONE, Luca; MAGRONE, Domenico; BARRECA, Giuseppe; RASPARINI, Marcello; LI MING, Huan Patent: WO2013/14191 A1, 2013 ; Location in patent: Page/Page column 19 ; |
|
~81%
Aliskiren hemif... CAS#:173334-58-2 |
| Literature: JUBILANT LIFE SCIENCES LIMITED; BISWAS, Sujay; SRIMURUGAN, Sankareswaran; KUMAR, Anjul; PANDA, Atulya, Kumar; JAMSHAD, Danish; MASAND, Mukesh; BISWAS, Bidyut; BANSAL, Vikas; GUPTA, Ashish, Kumar; VIR, Dharam Patent: WO2013/61224 A1, 2013 ; Location in patent: Page/Page column 25 ; |
|
~%
Aliskiren hemif... CAS#:173334-58-2 |
| Literature: WO2003/103653 A1, ; Page 196 ; WO 03/103653 A1 |
|
~%
Aliskiren hemif... CAS#:173334-58-2 |
| Literature: WO2012/52829 A1, ; Page/Page column 16-17 ; |
|
~%
Aliskiren hemif... CAS#:173334-58-2 |
| Literature: WO2011/148392 A1, ; |
|
~%
Aliskiren hemif... CAS#:173334-58-2 |
| Literature: WO2011/148392 A1, ; |
|
~%
Aliskiren hemif... CAS#:173334-58-2 |
| Literature: WO2012/52829 A1, ; |
|
~%
Aliskiren hemif... CAS#:173334-58-2 |
| Literature: WO2011/148392 A1, ; |
| Precursor 10 | |
|---|---|
| DownStream 1 | |
| CGP60536B |
| Aliskiren fumarate |
| tekturna |
| (2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide (2E)-2-butenedioate (2:1) |
| Aliskiren hemifumarate |
| (2E)-But-2-endisäure--(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamid(1:2) |
| Benzeneoctanamide, δ-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-γ-hydroxy-4-methoxy-3-(3-methoxypropoxy)-α,ζ-bis(1-methylethyl)-, (αS,γS,δS,ζS)-, (2E)-2-butenedioate (2:1) (salt) |
| CGP 60536 |
| (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide (2E)-but-2-enedioate (2:1) (salt) |
| Benzeneoctanamide, δ-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-γ-hydroxy-4-methoxy-3-(3-methoxypropoxy)-α,ζ-bis(1-methylethyl)-, (αS,γS,δS,ζS)-, (2E)-2-butenedioate (2:1
 ) (salt) |
| acide (2E)-but-2-ènedioïque - (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-diméthyl-3-oxopropyl)-4-hydroxy-7-[4-méthoxy-3-(3-méthoxypropoxy)benzyl]-8-méthyl-2-(1-méthyléthyl)nonanamide (1:2) |
| Rasilez |
| SPP 100 |
| (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide hemifumarate |
| benzeneoctanamide, δ-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-γ-hydroxy-4-methoxy-3-(3-methoxypropoxy)-α,ζ-bis(1-methylethyl)-, (αS,γS,δS,ζS)-, (2E)-2-butenedioate (2:1 |
| Aliskirenhemifumarate |
| Aliskiren (hemifumarate) |